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Context: Adenotonsillar tissue hypertrophy and obstructive sleep apnea have been reported dur-
ing short-term GH treatment in children with Prader-Willi syndrome (PWS).
Objective:We conducted an observational study to evaluate the effects of long-term GH therapy
on sleep-disordered breathing and adenotonsillar hypertrophy in children with PWS.
Design: This was a longitudinal observational study.
Patients and Methods: We evaluated 75 children with genetically confirmed PWS, of whom 50
fulfilled the criteriaandwereadmitted toour study. Thepatientswereevaluatedbefore treatment
(time 0 [t0]), after 6 weeks (t1), after 6 months (t2), after 12 months (t3), and yearly (t4–t6)
thereafter, for up to 4 years of GH therapy. The central apnea index, obstructive apnea hypopnea
index (OAHI), respiratory disturbance index, and minimal SpO2 were evaluated overnight using
polysomnography. We evaluated the adenotonsillar size using a flexible fiberoptic endoscope.
Results: The percentage of patients with an OAHI of 1 increased from 3 to 22, 36, and 38 at t1,
t4, and t6, respectively (2 12.2; P .05). We observed a decrease in the respiratory disturbance
index from1.4 (t0) to0.8 (t3) (P .05)andthecentral apnea index from1.2 (t0) to0.1 (t4) (P .0001).
We had to temporarily suspend treatment for 3 patients at t1, t4, and t5 because of severe ob-
structive sleep apnea. The percentage of patients with severe adenotonsillar hypertrophy was
significantly higher at t4 and t5 than at t0. The OAHI directly correlated with the adenoid size
(adjusted for age) (P  .01) but not with the tonsil size and IGF-1 levels.
Conclusion: Long-termGHtreatment inpatientswithPWS is safe; however,we recommendannual
polysomnography and adenotonsillar evaluation.
Prader-Willi syndrome (PWS) is a rare genetic diseasecharacterized by low birth weight, neonatal hypoto-
nia, poormuscle development, inadequate suction, genital
hypoplasia, small hands and feet, sticky saliva, short stat-
ure, temper tantrums, and mental retardation of variable
degree (1). Children with PWS are at risk of morbid obe-
sity caused by excessive attraction to food and lack of
satiety (2, 3). Central and obstructive sleep-disordered
breathing, often reported in children with PWS (1, 4),
causes poor sleep quality, excessive daytime sleepiness,
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and sedentary behavior with further increased risk of obe-
sity (5, 6). Obstructive sleep apneas (OSAs) may depend
not only on airway narrowing because of excessive fat but
also on airway collapse caused by pharyngeal wall hypo-
tonia and adenoid/tonsil hypertrophy (7). Additionally,
the central disordered breathing has been demonstrated to
be more severe in patients with PWS who exhibit hypo-
thalamic/pituitary adrenal insufficiency during stress (8).
Hypopituitarism due to hypothalamic dysfunction is well
established in PWS; GH replacement treatment has been
reported to be successful in promoting growth and im-
proving muscular trophism and tone, with a consequent
improvement in strength, agility, physical activity, and
cardiorespiratory function (9–11). From 2002 to 2005,
however, several cases of sudden death during the initial
phase of GH treatment have been reported (12–21). Au-
topsy findings showed, inmost cases, a significant increase
in lymphatic tissues, in particular, the adenoids and ton-
sils, supporting the hypothesis that airway obstruction is
the cause of death. Another possible explanation for the
cardiorespiratory impairment and eventually death dur-
ing GH treatment is that the antinatriuretic property of
GH results in cardiac overload (22). Short-term GH ad-
ministration has been demonstrated to stimulate the pro-
duction of immune system cytokines (23); thus, adeno-
tonsillar enlargement is also conceivable. Although in the
last 7 years there have been no reported deaths in patients
with PWS at the start of GH treatment, 2 reports have
demonstrated that sleep-disordered breathing may occa-
sionally occur inpatientswithPWSon long-termGHther-
apy (24, 25). In this article, we report the effect of GH
treatment on breathing during sleep, body weight, adeno-
tonsillar size, water retention, IGF-1, and insulin sensitiv-
ity in 50 children with PWS who were treated for up to 4
years.
Subjects and Methods
Subjects
Seventy-five children with PWS were consecutively enrolled
in thePediatricUnit of del PonteHospital inVarese fromJanuary
1, 2005, to December 31, 2010. The patients had been referred
from other Italian centers for polysomnographic assessment be-
fore starting GH treatment. Thirty-three patients had a deletion
of chromosome15q11–13; 36demonstratedmaternal disomyof
chromosome 15; and 6 showed only methylated DNA frag-
ments. As recommended by the Consensus Guidelines for GH
therapy in PWS (26), 25 patients who were markedly obese
and/or had severe OSAs did not start GH therapy and were ex-
cluded from the study.
In accordance with the study design, the remaining 50 pa-
tientswith PWSwere assessed beforeGH treatment (time 0 [t0]),
after 6weeks (t1), 6months (t2), and12months (t3) of treatment
and yearly thereafter (t4–t6) for up to 4 years (see biographical
data inTable 1).OnDecember31, 2012, 48of50patients (96%)
had completed 1 year, 22 of 50 (44%) completed 2 years, 12 of
50 (24%) completed 3 years, and 8 of 50 (16%) completed 4
years of GH treatment. All of the patients underwent biochem-
ical and anthropometric evaluation, polysomnography (PSG)
and otolaryngology (ENT) examinations. This study was ap-
proved by the local ethics committee. We obtained informed
written consent from the patients’ parents at t0.
Anthropometric evaluation
Supine length before the age of 2.5 years and height thereafter
were measured to the nearest millimeter using a Harpenden sta-
diometer, and weight was measured to the nearest 100 g using a
mechanical scale. Bodymass index (BMI)was calculated accord-
ing to the formula weight (kilograms)/height2 (square meters)
and expressed as z-score usingWorldHealthOrganization stan-
dards(27, 28).
Intracellular water estimate
Intracellular water was evaluated using multifrequency bio-
impedance analysis (Human-IM Scan; Dietosystem, Milan, It-
aly). The ratio of impedance at 100 to 1 kHz was used as the
index of intracellular water compartment extent (29).
Polysomnography
The PSG was performed using an e-Series PSG system (Com-
pumedics, Singen, Germany), and the following channels were
recorded: electroencephalographic leads (C3-A2, O2-A1, O1-
A2), left and right electro-oculograms, submental electromyo-
gram (using 2 electrodes located at the point of the chin and belly
of the digastric muscle on each side of the chin), electrocardio-
gram, airflow by nasal pressure transducer (similar to a nasal
cannula connected to a pressure transducer that provides a semi-
quantitative estimate of airflow based on pressure measure-
ment), respiratory effort by thoracic and abdominal strain
gauges, snoring noise by a microphone, arterial oxygen satura-
tion using a pulse oximeter (Xpod model 3011; Nonin Medical
Inc, Plymouth, Minnesota), and body position modification by
a sensor. TheAmericanAcademyof SleepMedicine criteriawere
used for PSG evaluation (30). OSAwas defined as a90%drop
in the signal amplitude of airflow for90% of the entire event,
compared with the pre-event baseline amplitude, and the final
event for at least 2 breaths (or the duration of 2 baseline breaths)
with continued inspiratory effort throughout the entire period of
decreased airflow. The obstructive apnea index was defined as
the number of OSAs per hour of total sleep time. Central apnea
was scored if the respiratory event was associated with absent
inspiratory effort throughout the duration of the event and if one
of the followingwas present: the event lasted20 seconds or the
event lasted at least 2 missed breaths and was associated with an
arousal, awakening, or a 3% desaturation. Central apnea in-
dex (CAI) was defined as the number of central apneas per hour
of total sleep time. Central apneas occurring immediately after a
sigh, movement or awakening were not included in the CAI.
Mixed apnea was defined as an apnea with both central and
obstructive components.Mixedapneaswere countedasobstruc-
tive apneas. Hypopnea was defined as a 50% drop in airflow
signal amplitude compared with the pre-event baseline ampli-
tude for at least 90%of the duration of the event.Hypopneawas
characterized as obstructive if the reduction in airflow was as-
sociated with paradoxical chest and abdominal movement or
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central if associated with an in-phase reduction in the amplitude
of chest and abdominal signals. The obstructive apnea hypopnea
index (OAHI) (30) was defined as the total number of OSAs,
mixed apneas, and obstructive hypopneas per hour of sleep.
The respiratory disturbance index (RDI) was defined as the
sum of all apneas (obstructive, central, and mixed) per hour of
total sleep time. The patients with an OAHI of1 were consid-
ered to have pathological obstructive sleep (31).
ENT examination
An ENT examination of the upper airways was performed
usinga2.4-mmFNL-7RP3 flexible fiberoptic endoscope (Pentax
Medical Company, Montvale, New Jersey) with topical anes-
thesia and video recording by 2 operators (P.C. andG.P.). Tonsil
hypertrophy was scored from 0 to4 (T0–T4) according to the
Brodsky criteria (32); adenoid hypertrophy was classified as the
proportion of airway patency reduction at vomer level into 4
categories (A0–A3) according to the criteria by Wang and col-
leagues (33). Moreover, the presence of acute or chronic inflam-
mation was evaluated by physical examination and anamnestic
investigation. The patients with acute upper airway inflamma-
tion received proper antibiotics and anti-inflammatory treat-
ment; they were reevaluated before starting GH treatment.
Biochemical evaluation
Blood samples for biochemical tests were taken after an over-
night fast. IGF-1 and insulin were measured in serum using an
RIA technique (Bioclone Australia Pty Limited, Marrickville,
Australia; Adaltis Italia SpA, Casalecchio di Reno, Italy). The
IGF-1 levels were standardized for age and gender by SDS trans-
formation using the laboratory reference values. Blood glucose
was measured in plasma using the HK-GSPDH method (Olym-
pus America Inc, Center Valley, Pennsylvania). Insulin sensitiv-
ity was assessed by homeostasis model assessment (HOMA)
(34).
GH treatment
The GH treatment was undertaken at a dosage ranging from
0.010 to 0.030 mg/kg/d. Both starting dosage and subsequent
adjustments of the therapy have been established on the basis of
a 15-point score (POI score) taking into account polysomno-
graphic parameters (RDI), size of tonsils and adenoids, and
IGF-1 levels (Table 2) (35).Thepredictivepowerof thePOI score
on adverse outcomes has not been established. However, we
decided to use this tool to better standardize the modulation of
the therapy.
Statistical analysis
The results are reported as the median, interquartile range,
and range. The sample size was sufficient to detect an OAHI,
RDI, and POI score change exceeding 0.17, 1.4, and 1.6, respec-
tively, with 95% confidence interval and 90% statistical
power. The statistical analysis of the continuous values before
Table 1. Auxological and Metabolic Findings Before and During GH Treatment in 50 Children With PWSa
GH Therapy Duration, mo
0 (t0) 1.5 (t1) 6 (t2) 12 (t3) 24 (t4) 36 (t5) 48 (t6)
n 50 50 38 48 22 12 8
Gender (male/
female)
24/26 24/26 23/15 23/25 9/13 8/4 5/3
Age, y 1.9 2.6 2.9 3.3 4.6 5.7 6.9
IQR 2.2 2.4 2.3 2.4 2.6 1.9 1.8
Interval 0.4–7.8 0.8–8.4 1.1–8.8 1.6–9.2 2.6–8.5 3.8–11.2 5.3–9.0
Length/height
(z-score)
1.8 1.8 1.6 1.5d 1.2b 1.6c 1.2
IQR 1.8 1.6 1.4 1.4 1.4 1.5 2.0
Interval 4.3 to 0.4 4.6 to 0.4 4.3 to 0.3 4.4 to 1.6 3.3 to 0.8 3.3 to 0.6 2.1 to 0.5
BMI (z-score) 0.40 0.41 0.32 0.38 1.10 1.34 1.43
IQR 1.84 1.88 2.20 2.52 2.03 1.57 1.43
Interval 2.7 to 2.9 2.7 to 2.9 1.8 to 3.0 3.28 to 3.3 1.7 to 2.9 0.3 to 2.7 0.0–2.6
IGF-1 (z-
score)
0.81 0.48c 0.07d 0.57d 1.23d 0.05 1.60c
IQR 1.95 1.85 1.12 1.20 1.52 2.06 0.78
Interval 6.44 to 1.632.49 to 4.07 4.91 to 2.22 1.75 to 4.23 1.39 to 3.33 1.80 to 1.50 0.23–2.58
HOMA 0.82 1.13d 1.07b
IQR 0.33 1.06 1.19
Interval 0.21–2.39 0.49–4.25 0.20–10.33
BIA, 100 Hz/1
Hz
0.847 0.865 0.869 0.864 0.858 0.815 0.825
IQR 0.090 0.060 0.042 0.054 0.095 0.123 0.036
Interval 0.517-
0.894
0.549–0.936 0.567–0.910 0.600–0.899 0.753–0.947 0.717–0.881 0.797–0.845
a The data are reported as the median along with interquartile range (IQR) and interval. Wilcoxon paired sign rank test was used to compare basal
(t0) parameters with those collected at a different duration time of the GH treatment (t1–t6).
b P  .05.
c P  .01.
d P  .001.
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and after GH treatment was performed using the nonparametric
pairedWilcoxon sign rank test, Friedman test, andKruskal-Wal-
lis test. Fisher’s exact test was used to compare the distribution
of the noncontinuous values. Statistical significance was set at
P  .05.
Results
Polysomnography
From t0 to t5, we observed an increase in the OAHI
(Table 3). In particular, 11 of 50 patients (22%) showed
an OAHI of1 during the treatment. Three patients had
to temporarily discontinue the GH treatment (at t1, t4,
and t5) because of POI scores of10, for periods ranging
from 2 to 4months. In 2 other patients, the GH treatment
was discontinued and not resumed in accordance with
parental request.Moreover, during the GH treatment, we
observed a significant improvement in the RDI primarily
due to a progressive decrease in the CAI over time (Table
3).
Otolaryngology
The ENT evaluation revealed a significant increase
(24% for adenoids and 15% for tonsils) in the per-
centage of patients showing more severe hypertrophy
(stage A3 and T4) at t4 and t5 (Figure 1). Previously
treated unsuccessfully with topical steroid, 1 patient re-
quired adenotonsillectomy at t3 and 2 patients at t5.
Because the adenotonsillar tissue in childhood changes
in size with age, achieving on average the largest volume
between 5 and8 years (36), tonsil and adenoid scoreswere
adjusted for age. The age-dependent component of ad-
Table 2. Summary of the Procedure for POI Score
Calculation and the Advice on the Modulation of GH
Therapy According to the Score Valuea
Values and Scores
PSG
Mean
SpO2,
%
97 95 95
Score0 1 2
RDI 1 1–3 3–5 5
Score0 2 3 4
Otorhinolaryngology
Tonsils
(degree),
%
0–25 25–50 50–75 75–100
Score0 1 2 3
Adenoids1/3 1/3 2/3 3/3
Score0 1 2 3
IGF-1,
percentile
25th 25–50th 50–75th 75th
Score0 1 2 3
Score Not yet on
treatment
In treatment
with GH
0–3 Start full dose Maintain or
increase
4–
6
Start 1/2 dose Maintain
7–9 Start 1/3 dose Decrease 50%
10 No start Stop therapy
a Permission to republish no. 11090171 obtained by Hormone
Research in Paediatrics) (38).
Table 3. Trend of Polysomnographic Parameters During GH Treatment in 50 Patients With PWSa
Time, mo
0 (t0) 1.5 (t1) 6 (t2) 12 (t3) 24 (t4) 36 (t5) 48 (t6)
n 50 50 38 48 22 12 8
OAHI 0.1 0.4b 0.3 0.6d 0.5c 0.7 0.7
IQR 0.5 0.9 0.6 0.9 1.2 0.8 1.3
Interval 0–1.2 0–15.8 0–3.7 0–3.0 0–7.7 0–3.2 0–3.2
OAHI 1, n (%) 3 (6) 11 (22) 8 (21) 10 (21)e 8 (36) 4 (33) 3 (38)
CAI 1.2 0.6c 0.2b 0.1d 0.0c 0.0d 0.0
IQR 2.7 1.9 1.7 0.9 0.3 0.0 0.2
Interval 0–12.1 0–7.8 0–4.0 0–4.5 0–0.9 0–0.8 0–0.5
RDI 1.4 1.5 0.7 0.8b 0.6 0.7 0.8
IQR 2.4 2.2 1.9 1.2 1.3 0.8 1.4
Interval 0–12.5 0–15.9 0–6.6 0–4.5 0–8.6 0–4.0 0–3.8
MinO2 88.0 86.5 85.0 86.2 83.5 87.0 85.0
IQR 6.5 9.0 9.0 12.0 12.0 14.5 8.5
Interval 71–94 60–94 55–94 67–97 53–94 59–95 78–97
a Unless indicated otherwise, the data are reported as the median along with interquartile range (IQR) and interval. Wilcoxon paired sign rank test
was used to compare basal (t0) parameters and those collected at a different duration of time of the GH treatment (t1–t6).
b P  .05.
c P  .01.
d P  .001.
e 2  12.2; P  .05.
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enotonsillar volume was obtained through a second-de-
gree regression model (stage A  0.742  0.358 age
(years) 0.039 age (years)2, R2 0.107, P .0001; and
stage T 1.036 0.367 age (years) 0.045 age (years)2,
R2 0.086, P .0001). The size of adenoids adjusted for
age was significantly related to the OAHI (Figure 2).
Auxological evaluation and intracellular water
estimate
During GH treatment, the BMI z-score and intracellu-
larwater compartment extent (estimated byBIA1kHz/00
kHz ratio) did not change significantly, whereas a signif-
icant increase was observed in height z-score, as deter-
mined by Wilcoxon sign rank paired test (Table 1).
IGF-1 and insulin sensitivity
During GH treatment, we observed a significant in-
crease in the IGF-1 level, whereas insulin sensitivity eval-
uated by HOMA did not change (Table 1).
POI score
Although mean POI score, a decisional tool recently
proposed for starting and adjusting GH therapy in chil-
dren with PWS (35), did not change significantly during
GH treatment, several patients showed a clear increase in
POI values above the 90th percentile during treatment
(Figure 3).
Discussion
Since 2000, GH has been registered by the U.S. Food and
Drug Administration and the EMEA for use in PWS with
and without GH deficiency. Although sudden deaths,
caused by suspected airway obstruction, have been re-
ported at the beginning (12–21), follow-up of subsequent
multiple cases (9–11) and randomized placebo-controlled
clinical studies (37, 38) have documented favorable effects
of the treatment not only on stature but also on lean mass
accretion, temper, and respiratory function. In a previous
study performed during the first 6 weeks of treatment, we
showed that the therapy is safe if it is initiated in lean
childrenwithoutOSAandwithpatent upper airways (39).
The overall results of this 48-month follow-up study con-
firm that GH treatment, on average, does not impair re-
spiratory function during sleep. In fact, during GH treat-
ment, we observed a significant improvement in the RDI,
primarily because of the progressive decrease in the CAI
over time. The most evident polysomnographic changes
during GH treatment were the reduction of CAI and the
increase of OAHI, the latter in lower proportion com-
pared with the reduction of CAI, leading to a reduction of
RDI achieving statistical significance at t3 (Table 3). RDI
instead of OAHIwas used in POI score for safety reasons,
assuming that the association ofOSA to CAImust be con-
sideredamajor risk for severe adverse events. BecauseRDI
accounts for both, it is, in our view, a more reliable risk
index.
Because of the lack of a control group, a weakness in
this study, we cannot conclude whether this improvement
is attributable to GH therapy. A recent 2-year follow-up
study on 15 childrenwith PWS, selectedwith criteria close
to those of our study, reached similar conclusions (25).
Additionally, we did not observe an overall significant
change in BMI, insulin sensitivity, or water retention, but
Figure 1. ENT evaluation.
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we observed a significant increase in stature and IGF-1
levels.
The originality of our study lies in the large number and
particular selection of patients (not severely obese and
without OSA and adenotonsillar hypertrophy at the start
of GH treatment) and in the prolonged observation time
(up to 48 months). Moreover, our study aimed to deter-
mine whether treatment with GH could cause, not only
worsen, preexisting hypertrophy of the tonsils and ade-
noids. We found a direct relationship between the OAHI
and the age-adjusted adenoid size, showing a probable
major causative role of adenoid hypertrophy in the patho-
genesis of OSA. The lack of a control group is again the
primary obstacle that prevents us from addressing the
question of whether GH causes adenotonsillar enlarge-
ment. However, age-adjusted adenotonsillar volume was
not correlated with standardized levels of IGF-1, making
it doubtful that GH has a dose-dependent effect on ad-
enotonsillar hypertrophy. It is, therefore, likely that other
GH-independent factors are responsible for the adenoton-
sillar hypertrophy andOSAs in patientswith PWS. In light
of this, it is important to bear in mind that tonsils and
adenoids undergo physiological hypertrophy during
childhood, peaking between 5 and 8 years of age (36). It
is, therefore, possible that in PWS patients who begin GH
treatment within the first 3 to 4 years of life, the progres-
sive adenotonsillar enlargement may be partially physio-
logical and thus independent of GH treatment. However,
because of the unpredictable occurrence of severe OSAs,
even during long-term GH therapy, prolonged PSG and
ENT follow-up must be recommended. Additionally,
Meyer et al (40) showed that adenotonsillectomy in PWS
can reduce mild to moderate OSAs but does not seem to
reduce severe sleep obstructive and central apneas. Con-
sequently, it would be appropriate to extend the ENT and
PSG monitoring to all of the subjects with PWS, not just
those who receive GH treatment.
In conclusion, the results of the present study show that
children with PWS can safely receive long-term GH treat-
ment; however, cautionmust be taken, particularly during
the first months of therapy, to avoid the possible devel-
opment or worsening ofOSAs. The observation of adeno-
tonsillar hypertrophy and OSAs in single patients even
after 2 ormore years of treatment suggests the importance
of PSG and ENT monitoring at least every year for the
entire duration of GH therapy.
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